Terlipressin (Terlivaz)

FDA-approved product existsPeptide

Awaiting review, BioHarmony verdict

Not yet scored. Queued for review; until then rely on the status and sources below.

What is Terlipressin (Terlivaz)?

FDA-approved terlipressin is marketed as Terlivaz to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.

Saved on this device only.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelTERLIVAZ prescribing information for hepatorenal syndrome with rapid reduction in kidney function
PopulationAdults covered by the approved TERLIVAZ indication
Dose0.85 mg by intravenous injection every 6 hours on days 1 through 3, followed by label-directed adjustment on day 4 based on serum creatinine change
RouteIntravenous injection through a peripheral or central line
FrequencyEvery 6 hours with label-directed reassessment and adjustment
DurationContinue until 24 hours after two consecutive qualifying serum creatinine values or for a maximum of 14 days
PreparationReconstitute each 0.85 mg vial with 5 mL of 0.9% Sodium Chloride Injection to make 0.85 mg/5 mL. Refrigerated reconstituted solution may be stored for up to 48 hours; do not freeze.
Source: Dosage and Administration sections 2.1-2.3; Dosage Forms and Strengths section 3

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingFDA-approved product exists; compounded copies are not FDA approved

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.